Casi pharmaceuticals report positive interim phase 1 data for bi-1206 in the treatment of relapsed/refractory indolent non-hodgkin's lymphoma in china

Beijing and lund, sweden , march 5, 2024 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and bioinvent international ab ("bioinvent") (nasdaq stockholm: binv), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced preliminary encouraging efficacy data for bi-1206 in combination with rituximab in patients with relapsed/refractory (r/r) indolent non-hodgkin's lymphoma (inhl) in the ongoing development program in china. bi-1206 is a first-in-class fully human monoclonal antibody (mab) that targets fcΓriib.
CASI Ratings Summary
CASI Quant Ranking